Bacillus amyloliquefaciensas prophylactic treatment forClostridium difficile-associated disease in a mouse model

Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials

(2014) Stuart Johnson et al.   CLINICAL INFECTIOUS DISEASES

A Lactobacillus casei Shirota probiotic drink reduces antibiotic-associated diarrhoea in patients with spinal cord injuries: a randomised controlled trial

(2013) Samford Wong et al.   BRITISH JOURNAL OF NUTRITION

Impact of adding prophylactic probiotics to a bundle of standard preventative measures forClostridium difficileinfections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital

(2013) P.-J. Maziade et al.   CURRENT MEDICAL RESEARCH AND OPINION

Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study

(2013) Arthur C. Ouwehand et al.   VACCINE

Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic

(2013) M. Hell et al.   Beneficial Microbes

A Meta-Analysis of Probiotic Efficacy for Gastrointestinal Diseases

(2012) Marina L. Ritchie et al.   PLoS One

Bacillus Coagulans GBI-30 (BC30) improves indices of Clostridium difficile-Induced colitis in mice

(2011) Leo R Fitzpatrick et al.   Gut Pathogens

Dose–Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium difficile-Associated Diarrhea Prophylaxis in Adult Patients

(2010) Xing Wang Gao et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A Mouse Model of Clostridium difficile–Associated Disease

(2008) Xinhua Chen et al.   GASTROENTEROLOGY